13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BGB-3111-304

    Acronym: 

    BGB-3111-304

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    An internation, phase 3, open-label, randomized study of BGB-3111 compared with Bendamustine plus Rituximab in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 U Hahn Recruiting